CervoMed releases corporate presentation highlighting neflamapimod Phase 2b efficacy signal in dementia with Lewy bodies
PUBT · 6d ago
Share
Listen to the news
- CervoMed highlighted Phase 2b data in dementia with Lewy bodies showing DP Batch B met exposure targets with clinically meaningful efficacy.
- CDR-SB improved versus placebo at 16 weeks, with a -1.12 difference in the planned Phase 3 population excluding AD co-pathology.
- Over 32 weeks, DP Batch B showed a -1.20 CDR-SB difference versus DP Batch A, described as an 89% reduction in decline.
- Progression risk fell with DP Batch B versus placebo, hazard ratio 0.49; versus DP Batch A, hazard ratio 0.46.
- Phase 3 planning calls for a single 32-week trial in about 300 patients using pTau181 under 21 pg/mL, with 50 mg TID dosing.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief on June 10, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved